Novo Nordisk A/S Class B NOVO_B
OMXCOP · Denmark · Health Technology
DKK 248.75-4.45 (-1.76%)
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Could this be what Novo needs to turn things around?
There could be more catalysts for the biotech over the next 18 months.
Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.
Investing.com -- Shares of Eli Lilly and Company (NYSE: LLY) climbed as much as 2.6% before settling up 0.5% after the pharmaceutical giant reported highly positive Phase 2b trial results for its new obesity and type 2 diabetes drug combination. As Lilly’s stock advanced, shares of primary competitor Novo Nordisk slipped 0.3% on the news.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.